These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 29743597)
1. MASTL overexpression promotes chromosome instability and metastasis in breast cancer. Rogers S; McCloy RA; Parker BL; Gallego-Ortega D; Law AMK; Chin VT; Conway JRW; Fey D; Millar EKA; O'Toole S; Deng N; Swarbrick A; Chastain PD; Cesare AJ; Timpson P; Caldon CE; Croucher DR; James DE; Watkins DN; Burgess A Oncogene; 2018 Aug; 37(33):4518-4533. PubMed ID: 29743597 [TBL] [Abstract][Full Text] [Related]
2. MASTL: A novel therapeutic target for Cancer Malignancy. Fatima I; Singh AB; Dhawan P Cancer Med; 2020 Sep; 9(17):6322-6329. PubMed ID: 32692487 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancer. Álvarez-Fernández M; Sanz-Flores M; Sanz-Castillo B; Salazar-Roa M; Partida D; Zapatero-Solana E; Ali HR; Manchado E; Lowe S; VanArsdale T; Shields D; Caldas C; Quintela-Fandino M; Malumbres M Cell Death Differ; 2018 May; 25(5):828-840. PubMed ID: 29229993 [TBL] [Abstract][Full Text] [Related]
4. MASTL inhibition promotes mitotic catastrophe through PP2A activation to inhibit cancer growth and radioresistance in breast cancer cells. Yoon YN; Choe MH; Jung KY; Hwang SG; Oh JS; Kim JS BMC Cancer; 2018 Jul; 18(1):716. PubMed ID: 29976159 [TBL] [Abstract][Full Text] [Related]
5. E2F8 confers cisplatin resistance to ER+ breast cancer cells via transcriptionally activating MASTL. Tian J; Lin Y; Yu J Biomed Pharmacother; 2017 Aug; 92():919-926. PubMed ID: 28605876 [TBL] [Abstract][Full Text] [Related]
6. The Greatwall kinase safeguards the genome integrity by affecting the kinome activity in mitosis. Bisteau X; Lee J; Srinivas V; Lee JHS; Niska-Blakie J; Tan G; Yap SYX; Hom KW; Wong CK; Chae J; Wang LC; Kim J; Rancati G; Sobota RM; Tan CSH; Kaldis P Oncogene; 2020 Oct; 39(44):6816-6840. PubMed ID: 32978522 [TBL] [Abstract][Full Text] [Related]
7. Loss of the Greatwall Kinase Weakens the Spindle Assembly Checkpoint. Diril MK; Bisteau X; Kitagawa M; Caldez MJ; Wee S; Gunaratne J; Lee SH; Kaldis P PLoS Genet; 2016 Sep; 12(9):e1006310. PubMed ID: 27631493 [TBL] [Abstract][Full Text] [Related]
8. MASTL is the human orthologue of Greatwall kinase that facilitates mitotic entry, anaphase and cytokinesis. Voets E; Wolthuis RM Cell Cycle; 2010 Sep; 9(17):3591-601. PubMed ID: 20818157 [TBL] [Abstract][Full Text] [Related]
9. MASTL(Greatwall) regulates DNA damage responses by coordinating mitotic entry after checkpoint recovery and APC/C activation. Wong PY; Ma HT; Lee HJ; Poon RY Sci Rep; 2016 Feb; 6():22230. PubMed ID: 26923777 [TBL] [Abstract][Full Text] [Related]
10. Knockdown of Microtubule Associated Serine/threonine Kinase Like Expression Inhibits Gastric Cancer Cell Growth and Induces Apoptosis by Activation of ERK1/2 and Inactivation of NF-κB Signaling. An CX; Xie SP; Li HL; Hu YH; Niu R; Zhang LJ; Jiang Y; Li Q; Zhou YN Curr Med Sci; 2021 Feb; 41(1):108-117. PubMed ID: 33582914 [TBL] [Abstract][Full Text] [Related]
11. MASTL promotes cell contractility and motility through kinase-independent signaling. Taskinen ME; Närvä E; Conway JRW; Hinojosa LS; Lilla S; Mai A; De Franceschi N; Elo LL; Grosse R; Zanivan S; Norman JC; Ivaska J J Cell Biol; 2020 Jun; 219(6):. PubMed ID: 32311005 [TBL] [Abstract][Full Text] [Related]
12. The MASTL/PP2A cell cycle kinase-phosphatase module restrains PI3K-Akt activity in an mTORC1-dependent manner. Sanz-Castillo B; Hurtado B; Vara-Ciruelos D; El Bakkali A; Hermida D; Salvador-Barbero B; Martínez-Alonso D; González-Martínez J; Santiveri C; Campos-Olivas R; Ximénez-Embún P; Muñoz J; Álvarez-Fernández M; Malumbres M EMBO J; 2023 Jan; 42(2):e110833. PubMed ID: 36354735 [TBL] [Abstract][Full Text] [Related]
13. The investigational Aurora kinase A inhibitor alisertib (MLN8237) induces cell cycle G2/M arrest, apoptosis, and autophagy via p38 MAPK and Akt/mTOR signaling pathways in human breast cancer cells. Li JP; Yang YX; Liu QL; Pan ST; He ZX; Zhang X; Yang T; Chen XW; Wang D; Qiu JX; Zhou SF Drug Des Devel Ther; 2015; 9():1627-52. PubMed ID: 25834401 [TBL] [Abstract][Full Text] [Related]
14. FYN promotes breast cancer progression through epithelial-mesenchymal transition. Xie YG; Yu Y; Hou LK; Wang X; Zhang B; Cao XC Oncol Rep; 2016 Aug; 36(2):1000-6. PubMed ID: 27349276 [TBL] [Abstract][Full Text] [Related]
15. Thrombocytopenia-associated mutations in Ser/Thr kinase MASTL deregulate actin cytoskeletal dynamics in platelets. Hurtado B; Trakala M; Ximénez-Embún P; El Bakkali A; Partida D; Sanz-Castillo B; Álvarez-Fernández M; Maroto M; Sánchez-Martínez R; Martínez L; Muñoz J; García de Frutos P; Malumbres M J Clin Invest; 2018 Dec; 128(12):5351-5367. PubMed ID: 30252678 [TBL] [Abstract][Full Text] [Related]
16. AKT Regulates Mitotic Progression of Mammalian Cells by Phosphorylating MASTL, Leading to Protein Phosphatase 2A Inactivation. Reshi I; Nisa MU; Farooq U; Gillani SQ; Bhat SA; Sarwar Z; Nabi N; Fazili KM; Andrabi S Mol Cell Biol; 2020 Apr; 40(10):. PubMed ID: 32123010 [TBL] [Abstract][Full Text] [Related]
17. The Oncogenic Functions of MASTL Kinase. Marzec K; Burgess A Front Cell Dev Biol; 2018; 6():162. PubMed ID: 30555827 [TBL] [Abstract][Full Text] [Related]
18. Downregulation of BAG‑1 in T47D cells promotes resistance to tamoxifen via activation of the PI3K/Akt/mTOR signaling pathway. Lu S; Du Y; Cui F; Feng X; Ma Y; Liu H Oncol Rep; 2019 Mar; 41(3):1901-1910. PubMed ID: 30747221 [TBL] [Abstract][Full Text] [Related]
19. PIK3R1 targeting by miR-21 suppresses tumor cell migration and invasion by reducing PI3K/AKT signaling and reversing EMT, and predicts clinical outcome of breast cancer. Yan LX; Liu YH; Xiang JW; Wu QN; Xu LB; Luo XL; Zhu XL; Liu C; Xu FP; Luo DL; Mei P; Xu J; Zhang KP; Chen J Int J Oncol; 2016 Feb; 48(2):471-84. PubMed ID: 26676464 [TBL] [Abstract][Full Text] [Related]
20. Mastl kinase, a promising therapeutic target, promotes cancer recurrence. Wang L; Luong VQ; Giannini PJ; Peng A Oncotarget; 2014 Nov; 5(22):11479-89. PubMed ID: 25373736 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]